Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.47 |
| ▸ | NPC1 | O15118 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB7A | P51149 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25370588 | 0.79 | ALDH1A1 (0.37) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1621825 | 0.77 | SMN1; SMN2 (0.56) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1622707 | 0.77 | ALDH1A1 (0.60) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1620159 | 0.76 | RAB9A (0.49) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1622373 | 0.75 | ALDH1A1 (0.53) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1621879 | 0.75 | ALDH1A1 (0.56) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1622875 | 0.74 | RAB9A (0.55) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1620748 | 0.74 | KDM4E (0.65) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1622286 | 0.73 | ALDH1A1 (0.50) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1622528 | 0.73 | ALDH1A1 (0.50) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573559-B1 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9603848-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8633186-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8541421-B2 | Methods of enhancing sweet taste of compositions using substituted thieno{2,3-D}pyrimidines | SENOMYX INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2573559-A1 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2568287-A2 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20110230502-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928111-B2 | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors | SENOMYX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2062050-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | Senomyx, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008154221-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306093-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230502-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | RAB9A 3534/4885NPC1 3785/4885MEN1 4289/4885 |
| US-20080306093-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | RAB9A 3534/4885NPC1 3785/4885MEN1 4289/4885 |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | RAB9A 3040/4885NPC1 2949/4885MEN1 4038/4885 |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | RAB9A 3534/4885NPC1 3785/4885MEN1 4289/4885 |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | RAB9A 3040/4885NPC1 2949/4885MEN1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.